SequelSEC

Solventum Corp SOLV

Surgical & Medical Instruments & Apparatus · CIK 0001964738 · Fiscal year ends 1231

Revenue
$8.32B
Fiscal year ended 2025-12-31
Operating income
$2.18B
Fiscal year ended 2025-12-31
Free cash flow
-$10.00M
Fiscal year ended 2025-12-31

Solventum Corp (SOLV) reported revenue of $8.32B and net income of $1.56B for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Solventum Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

Solventum Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Revenue$8.32B$8.25B$8.20B$8.13B
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profit$4.45B$4.59B$4.69B$4.70B
Operating income$2.18B$1.04B$1.69B$1.69B
Net income$1.56B$479.00M$1.35B$1.34B
Research & development$739.00M$775.00M$758.00M$767.00M
Weighted-average diluted sharesshares 175.30Mshares 173.70Mshares 172.70Mshares 172.70M
Pretax income$1.71B$605.00M$1.67B$1.69B
Income tax expense$157.00M$127.00M$321.00M$349.00M
Diluted EPS$8.88$2.76$7.79$7.78
Selling, general & administrative$3.08B$2.78B$2.30B$2.24B
General & administrativeUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Solventum Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$878.00M$762.00M$194.00MUnavailable
Total assets$14.29B$14.46B$13.94BUnavailable
Current assets$3.86B$3.25B$2.52BUnavailable
Total liabilities$9.24B$11.50B$2.28BUnavailable
Current liabilities$3.14B$2.70B$1.73BUnavailable
Total equity incl. NCI$5.05B$2.96B$11.67B$11.74B
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
Inventory$1.07B$965.00M$857.00MUnavailable
Accounts receivable$1.03B$1.04B$1.31BUnavailable
Goodwill$5.70B$6.38B$6.54B$6.43B
Long-term debt$5.04B$7.81B$0Unavailable
Accounts payable$687.00M$618.00M$477.00MUnavailable

Cash flow

Solventum Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow$369.00M$1.18B$1.92B$1.68B
Capital expenditures$379.00M$380.00M$290.00M$251.00M
Investing cash flow$2.80B-$380.00M-$230.00M-$253.00M
Financing cash flow-$3.06B-$240.00M-$1.55B-$1.46B
Net change in cash$116.00M$568.00M$133.00M-$30.00M
Stock-based compensation$161.00M$112.00M$39.00M$37.00M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$489.00M$555.00M$561.00M$578.00M

Derived

Solventum Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flow-$10.00M$805.00M$1.62B$1.43B
Gross margin53.5%55.6%57.3%57.7%
Operating margin26.2%12.6%20.6%20.8%
FCF margin-0.1%9.8%19.8%17.6%
SBC / revenue1.9%1.4%0.5%0.5%
Current ratio1.23x1.20x1.46xUnavailable
Revenue YoY growth0.9%0.7%0.8%Unavailable
Net margin18.7%5.8%16.4%16.5%
R&D / revenue8.9%9.4%9.2%9.4%
CapEx / revenue4.6%4.6%3.5%3.1%
Long-term debt / equity1.00xUnavailableUnavailableUnavailable
Effective tax rate9.2%21.0%19.3%20.6%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SOLV in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-27View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.